Swedish immuno-oncology company Alligator Bioscience earlier announced the promotion of
Laura von Schantz to the post of chief technology officer (CTO), and her joining the executive
management team.
In this role, Dr von Schantz Laura will oversee all technical aspects in the development of
Alligator’s best-in-class preclinical and clinical pipeline, including lead assets mitazalimab, a
CD40 agonist currently in Phase II clinical development, and ATOR-1017, a Phase II-ready 4-1BB
agonist.
Prior to that, Dr von Schantz was director, antibody engineering where she was responsible for
Alligator’s technology platform.
During her time with the company, Dr von Schantz has also been instrumental in the invention
of Alligator’s RUBY bispecific format and has led the establishment of antibody engineering that
can generate functional and developable candidate drugs at a competitive pace. She holds a
PhD in Immuno-technology and an MSc in Biotechnology, both from Lund University.
Alligator chief executive Søren Bregenholt commented: “It’s with great pleasure that we
welcome Laura to her new role as Alligator’s Chief Technology Officer and part of our executive
management team. Laura is the natural choice for the role to drive continued development of
Alligators technology platforms, while at the same time ensure we deliver on our internal and
partnered discovery programs. She has a deep knowledge of the company and our past
scientific achievements and future goals. Laura steps into the role at a pivotal time for Alligator
as we prepare to advance and expand our preclinical and clinical pipeline and we will benefit
greatly from her knowledge and expertise.”
https://www.thepharmaletter.com